Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.749